Milton Ault III Sells 37,738 Shares of Alzamend Neuro (NASDAQ:ALZN) Stock

Alzamend Neuro, Inc. (NASDAQ:ALZN) Director Milton Ault III sold 37,738 shares of Alzamend Neuro stock in a transaction on Friday, September 26th. The shares were sold at an average price of $2.31, for a total value of $87,174.78. Following the completion of the sale, the director directly owned 73,516 shares of the company’s stock, valued at approximately $169,821.96. This represents a 33.92% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Alzamend Neuro Price Performance

ALZN stock opened at $2.45 on Thursday. The stock has a 50-day moving average price of $2.42 and a two-hundred day moving average price of $4.19. Alzamend Neuro, Inc. has a 12-month low of $2.06 and a 12-month high of $17.10.

Institutional Investors Weigh In On Alzamend Neuro

An institutional investor recently bought a new position in Alzamend Neuro stock. Citadel Advisors LLC bought a new position in Alzamend Neuro, Inc. (NASDAQ:ALZN) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor bought 30,638 shares of the company’s stock, valued at approximately $36,000. Citadel Advisors LLC owned 0.56% of Alzamend Neuro at the end of the most recent reporting period. Hedge funds and other institutional investors own 49.61% of the company’s stock.

Analyst Upgrades and Downgrades

ALZN has been the subject of a number of research reports. Wall Street Zen downgraded Alzamend Neuro from a “hold” rating to a “sell” rating in a research report on Saturday, August 9th. Ascendiant Capital Markets decreased their target price on Alzamend Neuro from $45.00 to $42.00 and set a “buy” rating for the company in a research report on Thursday, September 25th. One research analyst has rated the stock with a Buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and a consensus target price of $42.00.

Alzamend Neuro Company Profile

Alzamend Neuro, Inc, an early clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. The company's pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002 stage, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient's immunological system to combat Alzheimer's disease.